Abstract
A simplified prognostic score is presented based on the multivariate analysis of 138 refractory/relapsed acute myeloid leukaemia (AML) patients (median age 55 years, range: 19–70) receiving a combination of intensive chemotherapy+Gemtuzumab as salvage regimen. Overall, 2-year event-free survival (EFS) and overall survival (OS) were 29±4% and 36±4%, respectively. Disease status (relapse <12 months, including refractory patients), FLT3-ITD-positive status and high-risk cytogenetics were the three strongest independent adverse prognostic factors for OS and EFS in this series. We then defined three subgroups with striking different outcomes at 2 years: no adverse factor (favourable, N=36): OS 58%, EFS 45%; one adverse factor (intermediate, N=54): OS 37%, EFS 31%; two or three adverse factors (poor, N=43): OS 12%, EFS 12% (P<10−4, P=0.001). This new simplified Leukemia Prognostic Scoring System was then validated on an independent cohort of 111 refractory/relapsed AML patients. This new simplified prognostic score, using three clinical and biological parameters routinely applied, allow to discriminate around two third of the patients who should benefit from a salvage intensive regimen in the setting of refractory/relapsed AML patients. The other one third of the patients should receive investigational therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Löwenberg B, Downing J, Burnett A . Acute myeloid leukemia, review article. N Engl J Med 1999; 341: 1051–1062.
Milligan DW, Grimwade D, Cullis JO, Bond L, Swirsky C, Craddock C et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006; 135: 450–474.
Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010; 115: 453–474.
Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinberg E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092–1099.
Breems DA, Van Putten W, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF et al. Prognosis index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23: 1969–1978.
Craddock C, Tauro S, Moss P, Grimwade D . Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 2005; 129: 18–34.
Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R et al. Long-term disease-free survival after Gemtuzumab, intermediate-dose cytarabine and Mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukaemia. J Clin Oncol 2008; 26: 5192–5197.
Chevallier P, Prebet T, Pigneux A, Hunault M, Delaunay J, Perry F et al. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including Gemtuzumab Ozogamicin. Leukemia 2010; 24: 467–469.
Filanovski K, Shvidel L, Shtalrid M . Advantage of MIDAM protocol in treatment of the elderly patients with refractory and relapsing acute myeloid leukemia. J Clin Oncol 2010; 28: e115.
Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela JM et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005; 106: 3618–3620.
Kiyoi H, Naoe T, Yokota S, Hamagushi M, Ohno R, Saito H et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997; 11: 1447–1452.
Lioure B, Delaunay J, Blaise D, Milpied N, Guardiola P, Cahn JY et al. Allogeneic stem cell transplantation (SCT) with non myeloablative conditioning regimen (NST) following intensive consolidation may be equivalent to conventional alloSCT and superior to autoSCT for patients over 50 with acute myeloid leukemia (AML) in 1st CR: first results of the AML 2001 trial. Blood (ASH Annual Meeting Abstracts) 2006; 108, abstract 319.
Chevallier P, Fornecker L, Lioure B, Bene MC, Pigneux A, Recher C et al. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial. Leukemia 2010; 24: 1380–1385.
Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W et al. Validation of the European Prognosis Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 2006; 134: 58–60.
Clarke WT, Marks PW . Gemtuzumab Ozogamicin: is there room for salvage? Blood 2010; 116: 2618–2619.
Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of Gemtuzumab Ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2010; 29: 369–377.
Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A et al. Compassionate-use of sorafenib in Flt3-ITD positive acute myeloid leukemia: sustained regression prior and post-allogeneic stem cell transplantation. Blood 2009; 113: 6567–6571.
Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562–569.
Acknowledgements
We would like to acknowledge the continuous support of the cell banking facility (‘tumurotheque’) of the CHU de Nantes, Angers, Limoges, Bordeaux, Marseille, Reims to their ongoing basic and clinical research work. We also thank all the data managers of the CHU de Nantes, Angers, Limoges, Bordeaux, Marseille, Reims, Rehovot and of the GOELAMS.
Author contributions
PC conceived and designed the study, analysed data, recruited patients, provided clinical care, performed bibliographic search and wrote the manuscript. JD recruited patients, provided clinical care, analysed data, performed the statistical analyses and helped in writing the manuscript. ML performed the statistical analyses. MM recruited patients, provided clinical care and helped in writing the manuscript. PT, TP, AP, MH, KF, IL, PCL, LL, SR, OB, NG, NV, NI, NM, JLH and MCB recruited patients, provided clinical care or performed biological analyses and commented on the manuscript. All the above authors approved the manuscript for publication purposes.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Chevallier, P., Labopin, M., Turlure, P. et al. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia 25, 939–944 (2011). https://doi.org/10.1038/leu.2011.25
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.25
Keywords
This article is cited by
-
Therapie der rezidivierten/refraktären akuten myeloischen Leukämie
Im Fokus Onkologie (2023)
-
Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia
Leukemia (2022)
-
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis
Annals of Hematology (2022)
-
Aktuelle Therapieoptionen bei rezidivierter/refraktärer AML
InFo Hämatologie + Onkologie (2022)
-
Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials
Annals of Hematology (2021)